CDK5/FBW7-dependent Ubiquitination and Degradation of EZH2 Inhibits Pancreatic Cancer Cell Migration and Invasion

Overview

Journal J Biol Chem

Specialty Biochemistry

Date 2017 Mar 1

PMID 28242758

Citations 62

Authors

Xin Jin

Chong Yang

Ping Fan

Jun Xiao

Wanli Zhang

Sudong Zhan

Tao Liu

Dejie Wang

Heshui Wu

Affiliations

Soon will be listed here.

Abstract

Pancreatic cancer is one of the most lethal cancer types. Enhancer of zeste homolog 2 (EZH2) is an oncogenic protein overexpressed in pancreatic cancer, and EZH2 could be a potential therapeutic target for the treatment of pancreatic cancer. Although significant progress has been made toward understanding the function and deregulation of EZH2 in cancer cells, the posttranslational regulation of EZH2 in cancer cells is still unclear. F-box and WD repeat domain-containing 7 (FBW7) acts as a tumor suppressor by targeting multiple oncoprotein substrates for ubiquitination and degradation. Here we demonstrate that EZH2 is a substrate of FBW7 in pancreatic cancer cells. We provide evidence that the activated CDK5 kinase is involved in the EZH2 phosphorylation that is required for FBW7-mediated degradation. We further show that FBW7 suppresses EZH2 activity and inhibits tumor migration and invasion via degradation of EZH2 in pancreatic cancer cells. Furthermore, immunohistochemistry analysis revealed that expression of EZH2 protein negatively correlates with FBW7 protein levels in a cohort of human pancreatic cancer specimens. Collectively, our findings demonstrate that FBW7 is a novel E3 ligase of EZH2 that regulates the EZH2 protein level in pancreatic cancer and represents a viable strategy for effective treatment of pancreatic cancer.

Citing Articles

CDK5: Insights into its roles in diseases.

Wang J, Zhang C, Jiang T, He Y, Wu Y, Zhou D Mol Biol Rep. 2025; 52(1):145.

PMID: 39836243 DOI: 10.1007/s11033-025-10253-4.

FBXW7 in gastrointestinal cancers: from molecular mechanisms to therapeutic prospects.

Wang W, Liu X, Zhao L, Jiang K, Yu Z, Yang R Front Pharmacol. 2025; 15:1505027.

PMID: 39749199 PMC: 11694028. DOI: 10.3389/fphar.2024.1505027.

PRMT6 facilitates EZH2 protein stability by inhibiting TRAF6-mediated ubiquitination degradation to promote glioblastoma cell invasion and migration.

Wang J, Shen S, You J, Wang Z, Li Y, Chen Y Cell Death Dis. 2024; 15(7):524.

PMID: 39043634 PMC: 11266590. DOI: 10.1038/s41419-024-06920-2.

Molecular insights and clinical implications for the tumor suppressor role of SCF E3 ubiquitin ligase.

Qi Y, Rezaeian A, Wang J, Huang D, Chen H, Inuzuka H Biochim Biophys Acta Rev Cancer. 2024; 1879(5):189140.

PMID: 38909632 PMC: 11390337. DOI: 10.1016/j.bbcan.2024.189140.

MicroRNAs as the critical regulators of epithelial mesenchymal transition in pancreatic tumor cells.

Tolue Ghasaban F, Ghanei M, Mahmoudian R, Taghehchian N, Abbaszadegan M, Moghbeli M Heliyon. 2024; 10(9):e30599.

PMID: 38726188 PMC: 11079401. DOI: 10.1016/j.heliyon.2024.e30599.

References

Sundqvist A, Bengoechea-Alonso M, Ye X, Lukiyanchuk V, Jin J, Harper J . Control of lipid metabolism by phosphorylation-dependent degradation of the SREBP family of transcription factors by SCF(Fbw7). Cell Metab. 2005; 1(6):379-91. DOI: 10.1016/j.cmet.2005.04.010. View

Le Bail O, Gonen H, Brou C, Logeat F, Six E, Ciechanover A . Functional interaction between SEL-10, an F-box protein, and the nuclear form of activated Notch1 receptor. J Biol Chem. 2001; 276(37):34371-8. DOI: 10.1074/jbc.M101343200. View

Reijm E, Timmermans A, Look M, Meijer-van Gelder M, Stobbe C, van Deurzen C . High protein expression of EZH2 is related to unfavorable outcome to tamoxifen in metastatic breast cancer. Ann Oncol. 2014; 25(11):2185-2190. DOI: 10.1093/annonc/mdu391. View

Nakajima T, Kitagawa K, Ohhata T, Sakai S, Uchida C, Shibata K . Regulation of GATA-binding protein 2 levels via ubiquitin-dependent degradation by Fbw7: involvement of cyclin B-cyclin-dependent kinase 1-mediated phosphorylation of THR176 in GATA-binding protein 2. J Biol Chem. 2015; 290(16):10368-81. PMC: 4400347. DOI: 10.1074/jbc.M114.613018. View

Chi P, Allis C, Wang G . Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer. 2010; 10(7):457-69. PMC: 3262678. DOI: 10.1038/nrc2876. View

Long J, Luo G, Xiao Z, Liu Z, Guo M, Liu L . Cancer statistics: current diagnosis and treatment of pancreatic cancer in Shanghai, China. Cancer Lett. 2014; 346(2):273-7. DOI: 10.1016/j.canlet.2014.01.004. View

The Lancet Oncology . Pancreatic cancer in the spotlight. Lancet Oncol. 2014; 15(3):241. DOI: 10.1016/S1470-2045(14)70097-X. View

Wu C, Jin X, Yang J, Yang Y, He Y, Ding L . Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer. Oncotarget. 2015; 7(3):3440-52. PMC: 4823118. DOI: 10.18632/oncotarget.6497. View

Welcker M, Clurman B . FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer. 2007; 8(2):83-93. DOI: 10.1038/nrc2290. View

10.

Ko H, Lee H, Huo L, Xia W, Yang C, Hsu J . GSK3β inactivation promotes the oncogenic functions of EZH2 and enhances methylation of H3K27 in human breast cancers. Oncotarget. 2016; 7(35):57131-57144. PMC: 5302978. DOI: 10.18632/oncotarget.11008. View

11.

Varambally S, Cao Q, Mani R, Shankar S, Wang X, Ateeq B . Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science. 2008; 322(5908):1695-9. PMC: 2684823. DOI: 10.1126/science.1165395. View

12.

Nateri A, Riera-Sans L, Da Costa C, Behrens A . The ubiquitin ligase SCFFbw7 antagonizes apoptotic JNK signaling. Science. 2004; 303(5662):1374-8. DOI: 10.1126/science.1092880. View

13.

Bohrer L, Chen S, Hallstrom T, Huang H . Androgens suppress EZH2 expression via retinoblastoma (RB) and p130-dependent pathways: a potential mechanism of androgen-refractory progression of prostate cancer. Endocrinology. 2010; 151(11):5136-45. PMC: 2954725. DOI: 10.1210/en.2010-0436. View

14.

Maskey D, Marlin M, Kim S, Kim S, Ong E, Li G . Cell cycle-dependent ubiquitylation and destruction of NDE1 by CDK5-FBW7 regulates ciliary length. EMBO J. 2015; 34(19):2424-40. PMC: 4601663. DOI: 10.15252/embj.201490831. View

15.

Ougolkov A, Bilim V, Billadeau D . Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2. Clin Cancer Res. 2008; 14(21):6790-6. PMC: 2690708. DOI: 10.1158/1078-0432.CCR-08-1013. View

16.

Tzatsos A, Paskaleva P, Ferrari F, Deshpande V, Stoykova S, Contino G . KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs. J Clin Invest. 2013; 123(2):727-39. PMC: 3561797. DOI: 10.1172/JCI64535. View

17.

Cao Q, Dhanasekaran S, Kim J, Mani R, Tomlins S, Mehra R . Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene. 2008; 27(58):7274-84. PMC: 2690514. DOI: 10.1038/onc.2008.333. View

18.

Strohmaier H, Spruck C, Kaiser P, Won K, Sangfelt O, Reed S . Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature. 2001; 413(6853):316-22. DOI: 10.1038/35095076. View

19.

Chen S, Bohrer L, Rai A, Pan Y, Gan L, Zhou X . Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2. Nat Cell Biol. 2010; 12(11):1108-14. PMC: 3292434. DOI: 10.1038/ncb2116. View

20.

Ji S, Qin Y, Shi S, Liu X, Hu H, Zhou H . ERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancer. Cell Res. 2015; 25(5):561-73. PMC: 4423074. DOI: 10.1038/cr.2015.30. View